This clinical trial is focused on studying intestinal giardiasis, a condition caused by a parasite that affects the digestive system, particularly in children. The trial will compare two treatments: quinacrine and metronidazole. Quinacrine is being tested in the form of capsules and tablets, while metronidazole is provided as tablets. The purpose of the study is to evaluate the safety and effectiveness of quinacrine in treating children with giardiasis that has not responded to standard treatments.

Participants in the study will receive either quinacrine or metronidazole. Quinacrine will be given at a dose of 6 mg per kilogram of body weight, three times a day, for five days. The study aims to see if quinacrine is as effective as metronidazole, which is the usual treatment for this condition. The trial will also monitor for any side effects and how well the children tolerate the medications.

The study will last for several years, with the goal of gathering enough information to determine the best treatment option for children with resistant giardiasis. Researchers will collect data on how well the treatments work in eliminating the parasite and any potential side effects experienced by the participants. This information will help in developing better treatment strategies for children affected by this condition.